TX SB883

Prohibits state officials, employees, or agents from restricting physicians from prescribing FDA-approved drugs for off-label use to treat patients exposed to or diagnosed with COVID-19

Prevents the Texas Medical Board from revoking, suspending, or taking adverse action against a physician's license solely for prescribing off-label drugs for COVID-19 treatment, provided the physician meets the medical standard of care

Shields drug manufacturers, physicians, and other healthcare providers from private or state lawsuits for harm resulting from off-label prescription drug use in COVID-19 treatment

Applies only to prescription drugs already approved by the FDA for human use, not experimental or unapproved medications

Takes effect immediately upon two-thirds vote of both legislative chambers, or September 1, 2025, otherwise